Skip to content

A multi center and cross sectional study for Chinese breast cancer patients with SERM treatment

A multi center and cross sectional study for Chinese breast cancer patients with SERM treatment

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-15006747
Enrollment
Unknown
Registered
2015-07-08
Start date
2015-01-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Patient sampling:Retrieve HR positive premenopausal breast cancer patients medical records in the corresponding month in 2009 (that is, 3 months, 6 months, 9 months and 12 months) from medical recor
Doctor sampling:Select 8 doctors each from the internal medicinedepartment and the surgical department of each mammary gland center.Sampling method by secret ballot method.

Sponsors

Chinese Anti-Cancer Association
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. population: women, 18-50 years old, before menopause; 2. Patients who underwent breast cancer radical surgery 5 years ago; 3. Histopathology of ER positive and / or PR positive; 4. Taking TAM and /or toremifene for adjuvant endocrine therapy after surgery; 5. Informed consent has been signed; 6. Patients with poor general condition, ECOG 3 or 4, can't be completed survey questionnaire independently, could authorize a legal principal to sign the informed consent and complete survey questionnaire truthfully.

Exclusion criteria

Exclusion criteria: 1. Consistent with the definition of menopause; 2. TAM or toremifene drug have been used, but the period less than 1 months; 3. Initial treatment for endocrine therapy using AI/TAM combined with LHRHa; 4. Patients with distant metastasis, such as bone, brain, lung metastasis, or residual tumor lesions have been found in 3 months after the operation from auxiliary examination ; 5. Other malignant tumors (not including basal cell carcinoma or endometrial cancer have been cured).

Design outcomes

Primary

MeasureTime frame
Adherence;Disease-free survival;Recurrence free survival;5 years survival rate;

Countries

China

Contacts

Public ContactBinghe XU
xubinghe@medmail.com.cn+86 13501028690

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026